NuCana plc

NuCana plc announced that the European Patent Office (EPO) has granted a composition-of-matter patent (EP 3683225) for its novel anti-cancer agent, NUC-7738. This patent is a key component of the company's intellectual property strategy, bringing the total number of worldwide issued patents for NUC-7738 to over 85. NUC-7738 is currently being evaluated in a Phase 1/2 clinical study. The company also stated that its cash resources are expected to fund operations into 2029.

NuCana plc reported a net loss of £3.1 million for the second quarter of 2026, a significant reduction from £24.1 million in the same period of 2025. For the first half of 2026, the net loss was £6.9 million, down from £26.6 million year-over-year. The company ended June 30, 2026, with £19.5 million in cash and cash equivalents, extending its cash runway into 2029. NuCana also announced the completion of patient recruitment for its Phase 2 NUC-7738 study, with final data expected later in 2026.

NuCana plc announced its second quarter 2026 financial results and provided updates on its clinical development programs. The company reported a significantly reduced net loss of £3.1 million for Q2 2026, a substantial improvement from £24.1 million in Q2 2025. NuCana also extended its cash runway, with current cash and cash equivalents of £19.5 million expected to fund operations into 2029. Recruitment for the Phase 2 expansion study of NUC-7738 is complete, with final data anticipated later in 2026, and the company is engaging with the FDA regarding a potential registrational strategy for NUC-7738 in melanoma.

NuCana plc conducted its Annual General Meeting (AGM) on June 8, 2026, in Edinburgh, United Kingdom. During the meeting, all resolutions that were outlined in the Company's notice of the AGM, dated May 6, 2026, were duly proposed and subsequently passed by the shareholders.

NuCana plc announced the appointment of Ian Webster as Chief Financial Officer, effective June 1, 2026. Mr. Webster has served as Interim Chief Financial Officer since June 2025 and was previously Director of Finance since joining the company in 2019. He will continue to serve as the Principal Financial Officer and Principal Accounting Officer, leveraging his over 20 years of finance experience to shape the company's financial strategy. NuCana also highlighted plans to generate data in 2026 from its Phase 2 NuTide:701 study and noted its cash runway is anticipated to extend into 2029.

NuCana plc reported a net loss of £3.9 million for the first quarter of 2026, an increase from £2.5 million in the prior year period, driven by higher research and development and administrative expenses. Despite the increased loss and a decrease in cash and cash equivalents to £21.5 million, the company announced its cash runway is expected to extend into 2029. Key business updates include the FDA clearance of its Investigational New Drug application for NUC-7738 in April 2026, with final data from the Phase 2 expansion study in melanoma anticipated later in 2026.

NuCana announced that its anti-cancer medicine NUC-7738 received FDA Investigational New Drug (IND) clearance in April 2026, enabling clinical investigation in the United States, with an initial focus on melanoma. The company also reported its Q1 2026 financial results, with cash and cash equivalents of £21.5 million as of March 31, 2026, which is expected to fund operations into 2029. NuCana continues to advance enrollment for its Phase 2 NuTide:701 expansion study of NUC-7738, with final data anticipated later in 2026, and is exploring additional indications and combination strategies for NUC-7738.

NuCana plc announced its 2026 Annual General Meeting (AGM) to be held on June 8, 2026, where shareholders will vote on several key resolutions. These include the re-election of directors, re-appointment of auditors, and approval of the 2025 financial accounts and remuneration reports. Crucially, the company is proposing a capital reorganisation involving the sub-division of both deferred and ordinary shares to address its inability to issue new ADSs at market value. Additionally, shareholders will vote on authorizing directors to allot shares and disapply pre-emption rights for up to £5,000,000, which the board deems essential for future financing and growth.